Cerebrolysin
![]() | This article may be expanded with text translated from the corresponding article in Russian. (July 2019) Click [show] for important translation instructions.
|
![]() Vial of the product | |
Clinical data | |
---|---|
Other names | FPF-1070 |
Identifiers | |
CAS Number |
|
DrugBank | |
UNII |
Cerebrolysin (developmental code name FPF-1070) is a mixture of enzymatically treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).
Cerebrolysin has also been studied for potential use with a wide variety of neurodegenerative disorders, though research is preliminary.[1] Cochrane reviews suggest no benefit in the treatment of acute stroke and an increased rate of spontaneous adverse events requiring hospitalization.[2] Conversely, reviews suggest positive effect when cerebrolysin is used with vascular dementia.[3] All Cochrane analysis to date stresses that these relationships needed to be confirmed by further high quality clinical trials.
Medical uses[]
Stroke[]
Reviews suggest no benefit for treatment of acute ischemic stroke with cerebrolysin, though they also emphasize the need for further high quality studies. In addition, cerebrolysin use was associated with a higher rate of spontaneous adverse events requiring hospitalization.[2] Studies of ischemic stroke in Asian subpopulations also found an absence of benefit.[4]
An early study also suggested a lack of benefit with hemorrhagic stroke related to cerebral aneurysm.[5]
Dementia[]
Reviews suggest an improvement in cognitive function with cerebrolysin use for vascular dementia, though as with studies on stroke, further high quality research is needed.[3]
Adverse effects[]
In trials studying the use of cerebrolysin after acute stroke, there was an increased risk of "serious adverse events" requiring hospitalization. These were specifically defined as:
- "...any untoward medical occurrence that, at any dose, resulted in death, [was] life‐threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, [was] a congenital anomaly/birth defect, or [was] a medically important event or reaction”.[2]
Mechanism of action[]
In vitro and animal studies suggest neurotrophic effects of cerebrolysin similar to endogenous neurotrophic factors, though its specific molecular pharmacodynamics are not clear.[6] Studies of dementia suggest decreased beta-amyloid deposition.[7]
History[]
The preparation was allegedly first created in 1949 by Gerhart Harrer, an Austrian professor at the University of Innsbruck.[citation needed]
Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.[2] It has been included on the list of Vital and Essential Medicines (ЖНВЛС) in Russia since 1992.[8]
Cerebrolysin is not a scheduled drug in the United States.[9][10]
Research[]
Early studies have suggested potential use of cerebrolysin with a wide variety of neurodegenerative disorders, including traumatic brain injury,[11][12] schizophrenia,[13] multiple sclerosis,[14] cerebral palsy[15] and spinal cord injury[16][17] though research is still preliminary.
References[]
- ^ Windisch M, Gschanes A, Hutter-Paier B (1998). "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation". Ageing and Dementia. Journal of Neural Transmission. Supplementa. Vol. 53. pp. 289–98. doi:10.1007/978-3-7091-6467-9_25. ISBN 978-3-211-83114-4. PMID 9700665.
- ^ a b c d Ziganshina, LE; Abakumova, T; Hoyle, CH (14 July 2020). "Cerebrolysin for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 7 (9): CD007026. doi:10.1002/14651858.CD007026.pub6. PMC 7387239. PMID 32662068.
- ^ a b Cui, S; Chen, N; Yang, M; Guo, J; Zhou, M; Zhu, C; He, L (11 November 2019). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD008900.pub3. PMC 6844361. PMID 31710397.
- ^ Heiss, WD; Brainin, M; Bornstein, NM; Tuomilehto, J; Hong, Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA), Investigators. (March 2012). "Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial". Stroke. 43 (3): 630–6. doi:10.1161/STROKEAHA.111.628537. PMID 22282884. S2CID 26004422.
- ^ Woo, PYM; Ho, JWK; Ko, NMW; Li, RPT; Jian, L; Chu, ACH; Kwan, MCL; Chan, Y; Wong, AKS; Wong, HT; Chan, KY; Kwok, JCK (3 November 2020). "Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage". BMC Neurology. 20 (1): 401. doi:10.1186/s12883-020-01908-9. PMC 7607674. PMID 33143640.
- ^ Plosker, GL; Gauthier, S (2009). "Cerebrolysin: a review of its use in dementia". Drugs & Aging. 26 (11): 893–915. doi:10.2165/11203320-000000000-00000. PMID 19848437.
- ^ Masliah E, Díez-Tejedor E (2012). "The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders". Drugs Today. 48 (Suppl A): 3–24. doi:10.1358/dot.2012.48(Suppl.A).1739716 (inactive 31 October 2021). PMID 22514792.
{{cite journal}}
: CS1 maint: DOI inactive as of October 2021 (link) - ^ распоряжением Правительства РФ от 7 декабря 2011 года № 2199-р
- ^ Rogers, Steve (29 October 2020). "Nicholasville compounding pharmacy, owner plead guilty to distribution". ABC 36 News.
- ^ "Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs Unlawful Distribution of Prescription Drugs". www.justice.gov. 24 February 2021.
- ^ Ghaffarpasand, F; Torabi, S; Rasti, A; Niakan, MH; Aghabaklou, S; Pakzad, F; Beheshtian, MS; Tabrizi, R (2019). "Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis". Neuropsychiatric Disease and Treatment. 15: 127–135. doi:10.2147/NDT.S186865. PMC 6311329. PMID 30643411.
- ^ El Sayed, I; Zaki, A; Fayed, AM; Shehata, GM; Abdelmonem, S (April 2018). "A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury". Neurosurgical Review. 41 (2): 427–438. doi:10.1007/s10143-016-0775-y. PMID 27539610. S2CID 3980956.
- ^ Xiao, S; Xue, H; Li, G; Yuan, C; Li, X; Chen, C; Wu, HZ; Mitchell, P; Zhang, M (February 2012). "Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms". The Australian and New Zealand Journal of Psychiatry. 46 (2): 153–60. doi:10.1177/0004867411433213. PMID 22311531. S2CID 206397952.
- ^ Khabirov, FA; Khaybullin, TI; Granatov, EV; Shakirzianova, SR (2016). "[Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 116 (12): 48–53. doi:10.17116/jnevro201611612148-53. PMID 28139626.
- ^ Nasiri, J; Safavifar, F (June 2017). "Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial". Acta Neurologica Belgica. 117 (2): 501–505. doi:10.1007/s13760-016-0743-x. PMID 28074392. S2CID 3805375.
- ^ Allam, AFA; Abotakia, TAA; Koptan, W (July 2018). "Role of Cerebrolysin in cervical spondylotic myelopathy patients: a prospective randomized study". The Spine Journal. 18 (7): 1136–1142. doi:10.1016/j.spinee.2017.11.002. PMID 29155000. S2CID 23283518.
- ^ Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012). "Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals". CNS Neurol Disord Drug Targets. 11 (1): 40–9. doi:10.2174/187152712799960781. PMID 22229324.
- Antidementia agents
- Neuroprotective agents
- Nootropics
- Peptides